Home › Funds › JANUS INVESTMENT FUND › Janus Henderson Triton Fund
Fund family: JANUS INVESTMENT FUND · Filed by JANUS INVESTMENT FUND (CIK 277751) · SEC series S000010485
Share classes and tickers: JANIX (C000083530), JATTX (C000028947), JGMAX (C000077722), JGMCX (C000077723), JGMIX (C000077726), JGMNX (C000114880), JGMRX (C000077725), JSMGX (C000077724)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 946 with, 11 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 5 FOR, 5 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as JANUS INVESTMENT FUND’s manager page (17,858 ballot items across 30 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | JANUS INVESTMENT FUND | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 94.9% | 906 | 97.2% | 15,061 |
| Backed environmental and social shareholder proposals at US companies | n/a | 1 | 3.6% | 392 |
Each ballot item this fund voted is set against the votes of the other JANUS INVESTMENT FUND funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most JANUS INVESTMENT FUND funds on 3 items (1.6% of the 186 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most JANUS INVESTMENT FUND funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Revolution Medicines, Inc. | 2026-06-18 | To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Alexis Borisy | Withhold | FOR — 7 of 9 JANUS INVESTMENT FUND funds | Against | Passed (calculated), 79.1% support |
| BridgeBio Pharma, Inc. | 2026-06-22 | To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares. | Against | FOR — 4 of 5 JANUS INVESTMENT FUND funds | Against | Approved, 82.9% support |
| BridgeBio Pharma, Inc. | 2026-06-22 | To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly ele | Withhold | FOR — 4 of 5 JANUS INVESTMENT FUND funds | Against | Passed (calculated), 80.1% support |
Download all 3 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 82.8% of this fund’s 957 such votes could be given a sector; the other 165 (17.2%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 200 | 1 | 0.5% |
| Industrials | 186 | 2 | 1.1% |
| Consumer Discretionary | 155 | 1 | 0.6% |
| Technology | 114 | 0 | 0.0% |
| Finance | 65 | 1 | 1.5% |
| Real Estate | 26 | 0 | 0.0% |
| Utilities | 14 | 1 | 7.1% |
| Energy | 10 | 0 | 0.0% |
| Telecommunications | 10 | 0 | 0.0% |
| Consumer Staples | 7 | 0 | 0.0% |
| Miscellaneous | 5 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 617 | 0 |
| Audit-related | 114 | 0 |
| Say-on-Pay | 107 | 0 |
| Compensation | 48 | 1 |
| Corporate Governance | 45 | 9 |
| Capital Structure | 20 | 0 |
| Extraordinary Transactions | 10 | 0 |
| Shareholder Rights and Defenses | 4 | 0 |
| Other | 2 | 0 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Glaukos Corporation | May 28, 2026 | $255M | 4 | 0 |
| Casey's General Stores, Inc. | September 3, 2025 | $172M | 15 | 1 |
| Teledyne Technologies Incorporated | April 22, 2026 | $149M | 6 | 0 |
| Ligand Pharmaceuticals Incorporated | June 5, 2026 | $146M | 11 | 0 |
| Aramark | February 3, 2026 | $133M | 13 | 0 |
| SS&C Technologies Holdings, Inc. | May 20, 2026 | $127M | 6 | 0 |
| Sensient Technologies Corporation | April 23, 2026 | $114M | 11 | 0 |
| Crown Holdings, Inc. | April 30, 2026 | $109M | 13 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| September 3, 2025 | Casey's General Stores, Inc. | Shareholder proposal regarding Scope 3 greenhouse gas reduction targets. Shareholder proposal | Against | For |
| April 30, 2026 | Crown Holdings, Inc. | Consideration of a Shareholder proposal regarding Shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 14, 2026 | Cboe Global Markets, Inc. | Stockholder proposal regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 13, 2026 | ICU Medical, Inc. | To approve, on an advisory basis, a stockholder proposal to establish a 10% stockholder special meeting right. Shareholder proposal | Against | For |
| April 28, 2026 | Revvity, Inc. | To approve the shareholder proposal regarding Executives to Retain Significant Stock. Shareholder proposal | Against | For |
| May 6, 2026 | Entegris, Inc. | Stockholder Proposal: Providing stockholders the right to call special meetings of stockholders. Shareholder proposal | For | Against |
| April 30, 2026 | NRG Energy, Inc. | To vote on a stockholder proposal to give shareholders the ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposal | For | Against |
| December 11, 2025 | Sportradar Group AG | Additional Voting Instructions - Shareholder Proposals (Voting) | Against | For |
| May 20, 2026 | Sportradar Group AG | Additional Voting Instructions - Shareholder Proposals (Voting) | Against | For |
| May 6, 2026 | Premium Brands Holdings Corporation | SP 1: Adopt and Disclose Policy to Review and Disclose Findings for Directors With Low Vote Support Shareholder proposal | Against | For |
| May 6, 2026 | Premium Brands Holdings Corporation | SP 2: Adopt and Disclose Policy to Regularly Disclose Director Voting Records Shareholder proposal | Against | For |
Meetings with a proxy contest or competing nominees (2 in 2025-2026), and how the fund voted the items on its ballot.
969 ballot items at 116 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Janus Henderson Triton Fund (JANIX) voted at 116 shareholder meetings of 113 companies, on 969 ballot items in all. Where management made a recommendation, the fund followed it on 98.9% of the items and voted against it 11 times. Its most frequent area of disagreement was corporate governance (9 of its votes against management). It voted on 10 shareholder proposals. It voted FOR the board's own proposals less often than JANUS INVESTMENT FUND's funds as a whole (94.9% against 97.2%). It voted differently from most JANUS INVESTMENT FUND funds on 3 items. 2 of its meetings were contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of JANUS INVESTMENT FUND’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.